Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality within the Veterans Healthcare Administration (VHA) and is frequently under-diagnosed. We developed the Veterans Airflow Screening Questionnaire (VAFOSQ) to improve the identification of Veterans with airflow obstruction (AFO), the most commonly used criterion for the diagnosis of COPD. We created an initial survey with 78 variables that have been associated with AFO. A total of 825 patients in 3 primary care clinics performed spirometry after bronchodilator administration and completed the initial survey. Best sets regression was used to build a model that predicted AFO optimally. A total of 195 of 825 (23.3%) patients had AFO and 7 items positively predicted AFO. When the questionnaire score was greater than 25, the VAFOSQ accurately identified AFO with an area under the receiver operating curve of 0.72. In a prospective validation cohort of 376 participants, the positive predictive value was 32% and negative predictive value 81%. The VAFOSQ is a reliable and valid instrument for the identification of veterans at risk for AFO who would benefit from further evaluation with spirometry and assessment for COPD. The VAFOSQ is straightforward to use and can be easily self-administered and self-scored enabling widespread application within the VHA. 
Chronic obstructive pulmonary disease (COPD) is an important cause of morbidity and mortality both in the United States and worldwide. 1-3 COPD is an underrecognized condition and diagnosis frequently does not occur until lung function is significantly diminished.
4
Increasing evidence suggests that early detection and intervention are the best methods of reducing the burden of COPD and improving the quality of life of patients with COPD. [5] [6] [7] [8] Spirometry is the best method to diagnose airflow obstruction (AFO) and a forced expiratory volume in 1 second (FEV1) to forced vital capacity (FVC) ratio less than either 0.7 or the lower limit of normal (LLN) are the usual thresholds for the presence of AFO.
The Third National Health and Nutrition Examination Survey (NHANES III) estimated the prevalence of COPD at 6.8% to 8.5% within the general U.S. population and a more recent Centers for Disease Control and Prevention questionnaire-based survey reported 6.3% of the population had been diagnosed with COPD.
9,10
Among veterans hospitalized in the VHA from 1997 to 2001, COPD was the fourth most common discharge diagnosis; approximately one third of all VHA patients and one sixth of all VHA inpatients had a diagnosis of COPD.
11 The prevalence of COPD in the VHA population is 33%-43% and COPD is also underdiagnosed in this population.
12
Recently, COPD diagnosis has been improved by the development of reliable screening questionnaires that identify individuals likely to have AFO and who are candidates for further evaluation with spirometry and assessment for COPD.
13 These questionnaires have, however, been developed and validated in samples of the general population or among those with pulmonary disorders.
14-16 The VHA patient population is significantly different from the general population -it is mostly male and older with a higher prevalence of both ever smoking and AFO.
12,17 Screening questionnaires designed and validated in the general population tend to be less accurate in the VHA population and there is a need for a VHA-specific COPD screening questionnaire to identify patients who would benefit from further evaluation with spirometry. Further, all questionnaires to date have used a fixed ratio threshold (FEV1/FVC<0.7) for the diagnosis of AFO rather than LLN (FEV1/FVC<LLN).
As part of a VHA quality improvement project
Introduction

Materials and Methods
Questionnaire Construction
Initial questionnaire development began with a synthesis of the literature reviewing common symptoms and historical factors in patients with AFO and COPD. These variables were organized into 5 conceptual domains: (1)functional impairment, (2) phlegm production, (3)history of upper respiratory tract infections, (4)history of chest congestion, cough and wheezing, and (5) 19 We selected the LLN as the threshold for the definition of AFO because it controls for age-related changes in the FEV1/ FVC which are not accounted for by the 0.7 fixed ratio threshold.
20,21
Spirometry tracings were reviewed by a pulmonologist to ensure adherence with ATS aimed at developing a patient-centered model for the management of COPD, we developed an AFO screening instrument to identify veterans with an increased risk for AFO and who might benefit from spirometry and assessment for COPD. Table 2 . A total of 630 patients (76.4%) had no AFO; 20 (2.4%) had mild AFO, 120 (14.5%) had moderate AFO, 42 (5.1%) had severe AFO, and 13 (1.6%) had very severe AFO based upon FEV1 %predicted. 20 Bronchodilator responsiveness (≥12% increase over baseline and ≥200ml) was present in 38 (19.5%) patients with AFO. In patients without AFO, bronchodilator responsiveness occurred in 11 (1.7%).
Initial Scoring
Item level missing data were mostly less than 4% except for a few items listed in Table 3 . Overall missing items accounted for 1.3% of the initial 78 item questionnaire. Table 4 shows the results of applying the final AFO screening questionnaire to the original dataset. The average score was 25.4 for patients with AFO and 20.9 for those without AFO. The mean VAFOSQ score increased as the severity of AFO worsened ( Table 4) . The score was 22.3 in patients with mild COPD, 25.1 in patients with moderate COPD, 26.3 in patients with severe COPD and 30.0 in patients with very severe COPD. Figure 1 shows the final screening questionnaire; within each response box is a shaded number that is the weighted score of that response.
Receiver operating characteristics (ROC) analysis was conducted to evaluate the VAFOSQ score in screening for AFO.
22 Table 5 shows the changes in sensitivity, specificity, positive predictive value, negative predictive value, and odds ratio of different total score thresholds. Lower cut-offs are associated with a higher sensitivity
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standards.
18 Only patients with spirometry tracings meeting ATS criteria were included in the analysis.
Statistical Analysis
We divided the complete sample (N=887) into a model building subset (n=600) and a retrospective validation subset (n=287). Using best-subsets regression, we identified the 10 best fitting combinations of predictors (from the initial set of 78 questions) for model sizes of 5 to 10 variables (an instrument with >10 questions was considered too lengthy). We then assessed which variables consistently appeared in the best fitting models (i.e., the proportion of times each variable appeared in the top models). This process identified 7 questions that showed the most robust association with AFO and we verified that combinations of these variables formed one of the best 7-variable models (this step was necessary to ensure that highly collinear variables with strong univariate associations with the outcome were not used together but rather that each variable contributed independent predictive power). To create a simple scoring algorithm based on summing Likerttype scores (ranging from 0 to 3), we iteratively tested various weightings of these variables to find a scoring that retained as much of the predictive power of the original regression equation as possible. The resulting screening instrument was scored prospectively in the validation sample to give an unbiased independent estimate of its predictive power in future applications in similar VHA populations.
Prospective Validation Testing
The 7 item Veterans AFO Screening Questionnaire (VAFOSQ) was validated prospectively in 3 VHA primary care clinics. For a period of approximately 3 months, all patients with a previously scheduled office visit were recruited for study participation and 380 patients completed the questionnaire. Spirometry was performed before and 10 minutes after albuterol administration via a metered-dose inhaler and a spacer according to ATS standards.
18
Test-Retest Study A subset of participants in the validation cohort were given the VAFOSQ and a stamped self-addressed envelope (n=45). They were asked to complete the VAFOSQ 2 weeks after participation in the validation study and return the questionnaire by mail for testretest reliability analysis. A total of 18 patients returned and lower specificity while higher scores provide a lower sensitivity and higher specificity. A total score threshold of 25 provided an optimal balance between sensitivity and specificity as well as high correct classification rates for AFO. Figure 2 shows the ROC curve and, at the selected threshold of 25, VAFOSQ sensitivity was 59.9% and specificity was 69.8% with an area under the curve of 0.72. A subset of the validation cohort completed the screening questionnaire, repeated it 2 weeks later, and returned the second response by mail. The average initial score was 26.5 and the average re-test score was 26.9. The overall correlation coefficient was 0.6.
Prospective Validation and Test-Retest Reliability
Discussion
We developed a brief, easy to complete AFO screening survey based upon patient reported information and validated the questionnaire in VHA primary care clinics. The survey was designed for ease of administration and can be completed by patients across a range of literary skills. The final VAFOSQ can be self-administered, increasing the reach and ease of screening. The VAFOSQ is administered and completed quickly and can be incorporated as part of routine screening at a primary care clinic visit. The questionnaire includes 7 items: (1)smoking history, (2)previously diagnosed history of anxiety, (3)chest tightness, (4)frequency of breathing problems, (5)frequency of frustration, (6)cough, and (7) history of noisy breathing. Because, unlike other COPD screening questionnaires, we utilized the LLN (which is age dependent) instead of a fixed ratio as the FEV1/FVC threshold for AFO, age was not a significant variable and was excluded from the final questionnaire. Some of the selected variables (history of anxiety) have not been included in previous COPD screening questionnaires; however, the combination of the 7 variables results in a highly predictive model. A weighted-sum of these items creates a score that differentiates between patients with and without AFO and the score magnitude correlates with COPD severity. The VAFOSQ scores correlate well with the presence of AFO and higher VAFOSQ scores indicate an increased likelihood of AFO. The mean VAFOSQ score is lowest in patients with no AFO and it increases gradually from mild to moderate to severe AFO. It is highest in patients with very severe AFO. Lower VAFOSQ threshold scores increase the detection of patients with AFO (higher sensitivity) but are also positive in an increased number of patients with no AFO (lower specificity). A threshold of 25 results in a sensitivity of 59.9%, a specificity of 69.8% and an area under the ROC curve of 0.72. Other potential applications of this survey in different populations may require a higher or lower cutoff for increased sensitivity or increased specificity.
Patients with COPD often fail to seek medical care for a variety of reasons; their symptoms progress gradually and they limit their activities to cope with worsening respiratory impairment. They do not realize their limitations are abnormal and that their symptoms can be improved.
23 COPD is underdiagnosed by 25%-50% in Italy.
24 In Spain, only 60% of patients with respiratory symptoms are seen by a provider and only 45% of them undergo spirometry testing.
25
Up to 80% of all individuals with AFO and half with severe AFO are not diagnosed.
26
Similarly, within the VHA, approximately two-thirds of individuals with AFO are not diagnosed with COPD.
12
Thus, COPD remains an under-recognized and underdiagnosed disease despite the ready availability of spirometry for measurement of AFO.
4,27 Often, a COPD diagnosis is delayed until the condition is advanced.
28
Spirometry is a reliable, simple, noninvasive, safe, and non-expensive procedure but it continues to be underutilized in the diagnosis of COPD because universal AFO screening is not recommended.
20,27,29
COPD screening questionnaires have proven to be useful in selecting patients for further evaluation with spirometry and use of these questionnaires encourages targeted deployment of health care resources.
13-16
Screening questionnaires that can be self-administered may aid in earlier COPD diagnosis which may improve clinical outcomes.
28-30
Among 342 patients hospitalized for the first time for a COPD exacerbation, 34% did not have a prior diagnosis of COPD and were not treated previously with any respiratory medication.
31 More of these previously undiagnosed patients quit smoking in the 3 months after hospitalization than did the diagnosed patients, 16%, versus 5%, 31 respectively. Patients diagnosed with AFO are more likely to quit smoking. an improvement in FEV1 in the first year after quitting and the subsequent rate of FEV1 decline is half the rate of continuing smokers and comparable to that of never-smokers. Thus, diagnosis of AFO may prompt initiation of both pharmacologic and non-pharmacologic treatments which may reduce the morbidity and mortality associated with COPD.
Based upon a systematic review of the benefits and harms of COPD screening, the U.S. Preventive Services Task Force recommends against screening asymptomatic adults for COPD.
38 However, the World Health Organization statement on the Global COPD and underestimate the severity of disease in 41 percent.
36 When these patients undergo spirometry, physicians change their severity assessments for 30% of patients and modify treatment in 37 percent.
36
In addition to smoking cessation, long-acting 
41
Empiric diagnosis of COPD based upon history and symptoms is often incorrect. Among 3209 Veterans treated empirically for COPD, only 62% had AFO. Older age, ever smoking, and underweight were associated with AFO whereas congestive heart failure, depression, diabetes, obesity, and sleep apnea were not.
42
Existing questionnaires for the identification of individuals at risk for AFO have been developed and validated in the general population. However, the VHA patient population is significantly different from the general population. It is older, overwhelmingly male, and has a higher prevalence of smoking and airways obstruction.
12
For these reasons, a questionnaire designed for a VHA patient population can be expected to have a lower false positive and a higher sensitivity and specificity in this population. Further, prior questionnaires have used a fixed ratio threshold for the definition of AFO; the VAFOSQ is the first screening survey to utilize the LLN threshold for AFO.
A limitation of our study includes the recruitment of participants from VHA primary care clinics. Recruited patients were presenting for an already scheduled primary care clinic visit for general medical problems which might confound the diagnosis of AFO. All patients were offered screening spirometry but patients with respiratory symptoms might be more likely to participate resulting in a higher prevalence of AFO in our cohort than in the general VHA patient population.
The VAFOSQ is a reliable and valid instrument for the identification of veterans at risk for AFO who would benefit from further evaluation with spirometry. The VAFOSQ is straightforward to use and can be easily self-administered and self-scored enabling widespread application throughout the VHA and, perhaps, the Department of Defense.
